A Randomized, Open-label, Single Dose, 2x2 Crossover Study to Evaluate the Safety and Pharmacokinetic Characteristics After Administration of Epaminurad in Healthy Adult Volunteers Under Fasting Conditions
Latest Information Update: 04 Feb 2026
At a glance
- Drugs Epaminurad (Primary)
- Indications Gout
- Focus Pharmacokinetics
- Sponsors JW Pharmaceutical
Most Recent Events
- 04 Feb 2026 New trial record